Connect Biopharma Holdings Ltd (CNTB) - Total Liabilities
Based on the latest financial reports, Connect Biopharma Holdings Ltd (CNTB) has total liabilities worth $11.99 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Connect Biopharma Holdings Ltd to assess how effectively this company generates cash.
Connect Biopharma Holdings Ltd - Total Liabilities Trend (2018–2024)
This chart illustrates how Connect Biopharma Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. Check CNTB asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Connect Biopharma Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of Connect Biopharma Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shree Pushkar Chemicals & Fertilisers Limited
NSE:SHREEPUSHK
|
India | Rs3.22 Billion |
|
Genesis Technology
TWO:6221
|
Taiwan | NT$2.80 Billion |
|
Bapcor Ltd
AU:BAP
|
Australia | AU$971.27 Million |
|
Asian Hotels (North) Limited
NSE:ASIANHOTNR
|
India | Rs12.92 Billion |
|
Acres Commercial Realty Corp
NYSE:ACR
|
USA | $1.25 Billion |
|
Baozun Inc
NASDAQ:BZUN
|
USA | $4.27 Billion |
|
AMPACS Corp.
TW:6743
|
Taiwan | NT$6.16 Billion |
|
Wam Alternative Assets Ltd
AU:WMA
|
Australia | AU$47.97 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Connect Biopharma Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CNTB company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Connect Biopharma Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Connect Biopharma Holdings Ltd (2018–2024)
The table below shows the annual total liabilities of Connect Biopharma Holdings Ltd from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.12 Million | -63.31% |
| 2023-12-31 | $24.85 Million | +47.86% |
| 2022-12-31 | $16.81 Million | -10.69% |
| 2021-12-31 | $18.82 Million | -94.18% |
| 2020-12-31 | $323.20 Million | +232.07% |
| 2019-12-31 | $97.33 Million | +9.73% |
| 2018-12-31 | $88.70 Million | -- |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as a… Read more